Henry Schein (NASDAQ:HSIC) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Henry Schein (NASDAQ:HSIC) from a buy rating to a hold rating in a report released on Sunday morning.

Several other brokerages have also recently issued reports on HSIC. Mizuho reduced their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. BMO Capital Markets initiated coverage on shares of Henry Schein in a report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target on the stock. Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. BTIG Research reiterated a “buy” rating and set a $100.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Piper Sandler boosted their price objective on Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $92.27.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $89.18 on Friday. Henry Schein has a 52 week low of $61.94 and a 52 week high of $92.18. The business’s 50 day moving average price is $83.98 and its 200 day moving average price is $78.81. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a market cap of $9.94 billion, a P/E ratio of 26.00, a P/E/G ratio of 1.68 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period last year, the firm posted $1.10 EPS. Henry Schein’s revenue for the quarter was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, sell-side analysts expect that Henry Schein will post 5.35 earnings per share for the current year.

Institutional Trading of Henry Schein

A number of hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in shares of Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after acquiring an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Henry Schein in the 1st quarter valued at about $676,000. Cetera Investment Advisers raised its holdings in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after purchasing an additional 637 shares during the period. Finally, First Trust Advisors LP raised its holdings in Henry Schein by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after purchasing an additional 1,669 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.